RIBOZYME AND OMICS

Announcement / News

News

Rznomics to Lead Next-Generation Gene Therapy with Trans-splicing Ribozyme Platform

  • 작성자
    관리자
  • 날짜
    2025-12-03
기사원문
Rznomics prepares Kosdaq debut on strength of RNA exchange enzyme platform
Rznomics Inc. (CEO Seong-Wook Lee) held an Investor Relations (IR) conference on the 3rd December, attended by the CEO and key executives, to share its strategic roadmap and vision following its upcoming listing on the KOSDAQ market.

Founded in 2017, Rznomics specializes in developing innovative therapies for cancer and rare intractable diseases using its proprietary RNA replacement enzyme-based RNA editing and correction platform. This platform is uniquely capable of performing three functions—targeting RNA cleavage, splicing, and replacement—within a single therapeutic agent. The technology is garnering significant attention from global pharmaceutical companies and academia due to its scalability across various mutations, its safety, and its optimized delivery efficiency tailored to specific indications.

The company’s lead pipeline asset, RZ-001, targets hepatocellular carcinoma (HCC) and glioblastoma (GBM). Both indications have received Orphan Drug Designation (ODD) and Fast Track Designation from the U.S. FDA, raising expectations for early commercialization. For glioblastoma, the therapy has been approved for an Expanded Access Program (EAP) and is currently being administered to patients. For hepatocellular carcinoma, Rznomics is conducting clinical trials in combination with immune-checkpoint inhibitors through clinical collaborations with Roche and Celltrion, which provide the necessary therapeutic agents for the trials free of charge.

Beyond RZ-001, the company maintains a diverse pipeline addressing high unmet medical needs, including RZ-003 for Alzheimer’s disease and RZ-004 for retinitis pigmentosa (RP), aiming to provide fundamental solutions for these conditions.

Rznomics’ technological benefit has been recognized both domestically and globally. Last year, the company was designated as the first "National Strategic Technology Company" and a "National Strategic Technology Possessing and Managing Company" by the Ministry of Science and ICT (MSIT) and the Korea Institute of Science & Technology Evaluation and Planning (KISTEP). Based on these credentials, Rznomics is pursuing the newly established "Deep Tech Special Listing". Upon listing, it is poised to become the first company among those managed by the MSIT to list under this specialized track.

In May, Rznomics validated its technological competitiveness and commercial potential by signing a strategic global licensing agreement with Eli Lilly and Company, valued at approximately KRW 1.9 trillion (USD 1.3 billion), to co-develop RNA editing therapies. This partnership is significant as it secures a first-mover advantage in the next-generation gene therapy market with proprietary RNA editing technology.

Rznomics plans to utilize the funds raised through its KOSDAQ listing to: advancing its RNA editing platform & accelerating global clinical trials and commercialization of core pipeline assets. Given the high scalability of its technology platform across various diseases, the company intends to expand collaborations with global pharmaceutical leaders through licensing and joint development based on its original patents and core technologies.

"Rznomics is presenting a new paradigm in the market for intractable cancer and rare disease treatments, where unmet medical needs are high, based on the world's first Trans-splicing Ribozyme platform," said Dr. Seong-Wook Lee, CEO of Rznomics. "We are committed to establishing our technology as the next-generation standard of care and evolving into a global leader in gene therapy, offering hope to patients suffering from intractable diseases."

Rznomics is offering 2,060,000 shares for public subscription. The indicative price range is set between KRW 17,000 and KRW 22,500, with a target fundraising amount of KRW 35.0 billion to KRW 46.4 billion. Demand forecasting for institutional investors will take place from November 27 to December 3, followed by public subscription on December 9 and 10. Samsung Securities and NH Investment & Securities are serving as the joint underwriters.
PREV
Rznomics to Participate in ‘BIO-Europe 2025’ to Expand Global Collaborations
LIST
LIST
NEXT
No Next Data.